News

Lupus Therapeutics, Takeda Launch Phase 1 Trial of TAK-079 for Moderate to Severe SLE

The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for the treatment of systemic lupus erythematosus (SLE) patients. The trial (NCT03724916), which will include approximately 24 participants across the U.S., is for patients with…

Physical Fitness Linked with Better Quality of Life in Women with SLE

Physical fitness, particularly muscle strength and cardiorespiratory fitness, are associated with better quality of life scores in women with systemic lupus erythematosus (SLE), a study reports. The study, “Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity,” was…

Discovery of Immune System Messenger May Advance Lupus Treatment

Researchers have identified a previously unknown mechanism by which cells that are infected can signal their neighbors that something is wrong. Understanding how this alarm signal works might lead to new strategies for shutting down harmful immune reactions in diseases like lupus. The study, “Intracellular bacteria engage…

Immune Regulator miRNA-142 Could Advance Cancer, Autoimmune Disease Research

A new study has identified a critical regulator of immunity, called microRNA-142, which could have significant implications for understanding or even treating autoimmune diseases and cancer. The study, “microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance,” was published in The Journal of Clinical Investigation. The…